Aging is a disease of lost information you can treat

1

Aging as a disease

Classifying aging itself as a treatable disease, not background fate, is the reframing that unlocks trials, funding, and the whole research program.

Sinclair rejects the medical convention that splits heart disease, cancer, and dementia into unrelated ailments. He treats them as downstream symptoms of one upstream process: aging.

Because no country’s system officially names aging a disease, it cannot enter drug trials the way cancer can. That gap starves the field of money and regulatory paths. He notes the World Health Organization’s ICD system only recently added an extension code for aging-related pathology, proof the classification fight is already underway.

If aging is the shared cause of most late-life illness, hitting it directly would spend medical resources more efficiently than chasing each symptom alone. Gerontologists who prefer “healthspan” talk without medicalizing aging cite legal, insurance, and pathologizing risks. Sinclair’s answer is pragmatic: he wants the disease label for FDA structures, not to settle what aging “really” is.

In practice: He contrasts two 70-year-olds with the same chronological age—one still running marathons, one in a wheelchair—to show years lived are a poor proxy for the process worth treating.

2

Lost epigenetic information

Aging comes mainly from lost epigenetic instructions that keep cell identity, not from mutated DNA or accumulated molecular junk.

Building on the disease frame, Sinclair’s core mechanism separates the genome from the epigenome. The genome is digital hardware—the DNA sequence, backed up and relatively stable. The epigenome is software: chemical marks such as DNA methylation that tell a skin cell to act like skin and a neuron like a neuron.

His repeated analogy is a scratched compact disc. The music is still encoded; the reader fails, so you hear static and skips. If aging is degraded readout of intact information, it is recoverable in principle—resurfacing the disc—unlike theories that treat aging as a one-way slide of irreversible damage.

His lab’s 2020 work used three of the four Yamanaka reprogramming factors (OCT4, SOX2, KLF4, omitting MYC to reduce cancer risk) on mouse retinal ganglion cells. The reset restored vision in mice with induced glaucoma and in aged mice by rolling epigenetic marks toward a younger pattern without erasing cell identity.

That result is the book’s most aggressive scientific claim and its most contested. Critics call it a single study in one cell type, far from safe whole-body reversal. Still, the theoretical move carries the rest of the argument: recoverable information, not pure entropy.

In practice: Partial Yamanaka-factor reprogramming restored vision in glaucomatous and aged mice by resetting epigenetic marks without wiping cell identity.

3

The sirtuin survival circuit

Sirtuins are an ancient stress switch that steers cells from reproduction toward repair, and flipping that switch extends lifespan across species.

Sinclair narrows to the enzymes that defined his career. Sirtuins in yeast, worms, and mice respond to stressors such as calorie restriction by pushing cells into defensive repair instead of growth-and-reproduce mode.

Early yeast work showed that boosting a sirtuin gene called SIR2 extended replicative lifespan. Mammals carry seven sirtuins, SIRT1 through SIRT7, with roles in metabolism, inflammation, and DNA repair. The survival-circuit story says famine or hardship favored individuals who paused reproduction and spent resources on maintenance.

That framing is meant to explain why mild stressors—caloric restriction, cold exposure, intense exercise—extend lifespan across lab species: they trip a conserved alarm, not a human-only trick. Primate calorie-restriction studies at the University of Wisconsin and the NIA improved health markers, though maximum-lifespan effects stayed contested because diet composition and control feeding differed between the two long trials.

The setup is deliberate. If starving or freezing yourself can flip the circuit, chemistry might flip it too—without the misery—opening the door to activating molecules and caloric-restriction mimetics.

In practice: Boosting yeast SIR2 extended replicative lifespan and later mapped onto seven mammalian sirtuin genes tied to repair and metabolism.

4

Molecules that mimic hardship

Resveratrol, NMN, and metformin can activate the same survival pathways as fasting and exercise, offering a chemical shortcut without the hardship.

With the circuit named, Sinclair turns to pharmacology. Resveratrol from red wine and grape skins activated SIRT1 in his lab’s 2003 and 2006 papers and extended lifespan in yeast, worms, and obese mice. Public frenzy followed. He founded Sirtris Pharmaceuticals, later bought by GlaxoSmithKline for roughly 720 million dollars in 2008.

He is candid that human results disappointed enough for GSK to shelve the resveratrol-derivative programs. He reads that as a bioavailability and formulation failure, not a refutation of the pathway. He then pivots to NAD+ precursors, especially NMN, arguing NAD+ declines with age and that restoring it reactivates sirtuins.

He discloses personal use of NMN and metformin, the diabetes drug a retrospective 2014 UK study by Bannister and colleagues linked to lower mortality in diabetics than in non-diabetic controls. He flags the limits: none of these compounds has finished large, long, randomized human trials that prove lifespan benefit, and his regimen is a self-experiment, not a prescription.

The chapter’s real point is generative: the sirtuin theory yields swallowable, testable hypotheses. The unresolved problem remains the jump from promising mouse data to confirmed human years.

In practice: Sirtris, built on resveratrol-pathway drugs, sold to GlaxoSmithKline for roughly 720 million dollars in 2008 before human programs were later shelved.

5

Rapamycin and mTOR

Dialing down the nutrient sensor mTOR with rapamycin is among the most reproducible lifespan extenders ever tested in mammals—up to 25 percent median gain in mice.

Sinclair adds a second major pathway beside sirtuins. mTOR senses amino acids and nutrient abundance; when food is plentiful it drives growth and suppresses autophagy, the cell’s cleanup routine.

Rapamycin, isolated from bacteria in Easter Island soil and used as a transplant immunosuppressant, inhibits mTOR. The NIA’s Interventions Testing Program, a multi-lab consortium, found it extended median lifespan in genetically diverse mice by as much as 25 percent even when started in middle age—one of the field’s most reproducible results.

He treats this as evidence that longevity is a network, not a single dial: sirtuins, mTOR, and AMPK converge on repair-over-growth. The practical snag is immune suppression at transplant doses, so researchers such as Matt Kaeberlein have explored intermittent low-dose regimens to keep the longevity benefit without that cost.

Redundant overlapping systems raise hopes for combinations and raise the difficulty of predicting side effects, since helping one pathway may stress another.

In practice: The NIA Interventions Testing Program reported rapamycin lifted median lifespan as much as 25 percent in diverse mice even from a midlife start.

6

Measuring biological age

Epigenetic clocks that read DNA methylation gauge how fast someone is aging better than birthdays and could turn decades-long trials into month-scale tests.

None of the earlier interventions can be judged if the only endpoint is death. Sinclair describes clocks pioneered by Steve Horvath that measure methylation at chosen genomic sites and estimate biological age from blood or tissue, sometimes years above or below chronological age.

He casts the clocks as validation of the information theory: they read epigenetic pattern, not mutation load or telomere length, which makes epigenetic drift the more useful meter to track.

Once cheap, reliable biological-age tests spread, aging research changes shape. Instead of waiting decades for mortality shifts, a lab could see whether a compound moves a clock backward in months.

He admits the tech is immature, that clocks trained on one population or tissue often fail elsewhere, and that the FDA has not accepted biological age as a trial endpoint. That policy bottleneck, he argues, binds the field as tightly as any molecular gap. The chapter is the hinge from lab story to forecast: near-term optimism needs these meters to work.

In practice: Horvath-style methylation clocks can peg biological age years away from birthday age and, if accepted, could shorten efficacy readouts to months.

7

A world without aging

Within decades, medicine could shift from treating each age-related disease to slowing or reversing aging itself, forcing healthcare, money, and culture to rebuild.

In the most speculative chapter, Sinclair lays out a timeline. Within his own lifetime, he predicts, combinations of epigenetic reprogramming, NAD+ boosters, and senolytics—drugs that clear senescent “zombie” cells, an approach pioneered by James Kirkland and colleagues at Mayo Clinic—could add meaningful healthy years. Eventually aging might slow enough that 100 becomes an unremarkable age to reach in good health.

Institutions are unready. Pension systems, retirement ages, and career ladders assume a fixed decline curve. Culture still narrates old age as unavoidable fade rather than a treatable state.

He faces the hard objections instead of dodging them. Expensive longevity therapies could widen rich-poor gaps dramatically. If population keeps rising while fewer people die, resource strain intensifies. His reply is historical pattern: vaccines, antibiotics, and clean water looked elite before they became cheap and universal. He does not supply strong evidence that complex biologics will follow the same cost curve.

Here the voice shifts from lab reporter to public advocate. Pursuing longevity science, he argues, is a moral imperative against a major cause of suffering, and much resistance is failure of imagination more than a hard scientific ceiling.

In practice: He groups NAD+ boosters and reprogramming with Kirkland’s Mayo Clinic senolytics as a near-future mix that could make healthy 100s ordinary.